By allowing cancer centers to extend their Cancer Center Support Grant award period from five to seven years, NCI hopes to enable eligible centers to spend less time preparing for a grant renewal in favor of conducting more research and setting long-term goals.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
